TMIC-61. LOSARTAN PREVENTS IMMUNOTHERAPY-ASSOCIATED EDEMA AND ENHANCES SURVIVAL IN GLIOBLASTOMA
Meenal Datta(University of Notre Dame), Mitrajit Ghosh(Harvard University), Kyrre E. Emblem(Oslo University Hospital), Mario L. Suvà(Broad Institute), Sylvie Roberge(Harvard University), Lei Xu(Fudan University), Sampurna Chatterjee(Harvard University), M. Grazia Speranza(University of Brescia), Arlene H. Sharpe(Brigham and Women's Hospital), Mark Duquette(Boston University), David A. Reardon(Dana-Farber Cancer Institute), Kamila Naxerova(Harvard University), Pragya Kumar(Boston University), Ashwin S. Kumar(Harvard University), Ivy Chen(Harvard University), Simon Gritsch(Broad Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Xinyue Dong(Universiti Malaysia Pahang Al-Sultan Abdullah), Rosa Ng(Boston University), Elizabeth Perez(Boston University), William Ho(Baker Heart and Diabetes Institute), Shanmugarajan Krishnan(University Hospital of Zurich), Martha R. Neagu(Columbia University)
Cited by 0
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Multi-criteria decision making approaches for supplier evaluation and selection: A literature review
|European Journal of Operational Research|2009|2.2k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k